Processa Pharmaceuticals, Inc. Net Cash Provided by (Used in) Operating Activities, Continuing Operations
Processa Pharmaceuticals, Inc. (PCSA) reported Net Cash Provided by (Used in) Operating Activities, Continuing Operations of $2.20 million for the 6-month period ending 2018-06-30, per its 10-Q filed 2018-08-14.
Discontinued › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations · last filed 2018-08-14
- Processa Pharmaceuticals, Inc. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2017-12-31 was -$1.41M.
- Processa Pharmaceuticals, Inc. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2017-09-30 was -$173.69K, a 1135.21% decline year-over-year.
- Processa Pharmaceuticals, Inc. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2017-06-30 was -$74.69K.
- Processa Pharmaceuticals, Inc. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2017-03-31 was -$1.60K.
- Processa Pharmaceuticals, Inc. net cash provided by (used in) operating activities, continuing operations for fiscal 2017 was -$1.66M.
- Processa Pharmaceuticals, Inc. net cash provided by (used in) operating activities, continuing operations for fiscal 2016 was -$30.85K.
- Processa Pharmaceuticals, Inc. net cash provided by (used in) operating activities, continuing operations for fiscal 2015 was -$639.55K.
- Processa Pharmaceuticals, Inc. net cash provided by (used in) operating activities, continuing operations for fiscal 2014 was -$1.91M.
| Period end | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 3 month as first filed | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 6 month as first filed | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 9 month as first filed | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 12 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2018-06-30 | $2.20M 10-Q · filed 2018-08-14 | |||||||
| 2017-12-31 | -$1.41M derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-16 | -$1.58M derived: sum of 2 quarters · filed 2018-04-16 | -$1.65M derived: sum of 3 quarters · filed 2018-04-16 | -$1.66M 10-K · filed 2018-04-16 | ||||
| 2017-09-30 | -$173.69K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-20 | -$248.38K derived: sum of 2 quarters · filed 2017-11-20 | -$249.97K 10-Q · filed 2017-11-20 | -$253.43K derived: sum of 4 quarters · filed 2017-11-20 | ||||
| 2017-06-30 | -$74.69K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-10-04 | -$76.29K 10-Q · filed 2017-10-04 | -$79.74K derived: sum of 3 quarters · filed 2017-10-04 | -$62.97K derived: sum of 4 quarters · filed 2017-11-20 | ||||
| 2017-03-31 | -$1.60K 10-Q · filed 2017-10-04 | -$5.05K derived: sum of 2 quarters · filed 2017-10-04 | $11.72K derived: sum of 3 quarters · filed 2017-11-20 | $11.45K derived: sum of 4 quarters · filed 2017-11-20 | ||||
| 2016-12-31 | -$3.46K derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-25 | $13.32K derived: sum of 2 quarters · filed 2017-11-20 | $13.05K derived: sum of 3 quarters · filed 2017-11-20 | -$30.85K 10-K · filed 2017-09-25 | ||||
| 2016-09-30 | $16.78K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-20 | $16.50K derived: sum of 2 quarters · filed 2017-11-20 | -$27.40K 10-Q · filed 2017-11-20 | -$97.19K derived: sum of 4 quarters · filed 2017-11-20 | ||||
| 2016-06-30 | -$276.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-10-04 | -$44.18K 10-Q · filed 2017-10-04 | -$113.97K derived: sum of 3 quarters · filed 2017-10-04 | -$141.83K derived: sum of 4 quarters · filed 2017-10-04 | ||||
| 2016-03-31 | -$43.90K 10-Q · filed 2017-10-04 | -$113.70K derived: sum of 2 quarters · filed 2017-10-04 | -$141.55K derived: sum of 3 quarters · filed 2017-10-04 | -$330.60K derived: sum of 4 quarters · filed 2017-10-04 | ||||
| 2015-12-31 | -$69.80K derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-25 | -$97.65K derived: sum of 2 quarters · filed 2017-09-25 | -$286.70K derived: sum of 3 quarters · filed 2017-09-25 | -$639.55K 10-K · filed 2017-09-25 | -$639.50K 10-K · filed 2017-06-19 | |||
| 2015-09-30 | -$27.86K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-09-08 | -$216.91K derived: sum of 2 quarters · filed 2017-09-08 | -$569.75K 10-Q · filed 2017-09-08 | -$826.00K 10-Q · filed 2015-12-01 | -$245.73K derived: sum of 4 quarters · filed 2017-09-08 | |||
| 2015-06-30 | -$189.05K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-30 | -$541.90K 10-Q · filed 2017-08-30 | -$779.00K 10-Q · filed 2015-08-19 | -$217.87K derived: sum of 3 quarters · filed 2017-08-30 | -$758.11K derived: sum of 4 quarters · filed 2017-08-30 | |||
| 2015-03-31 | -$352.85K 10-Q · filed 2017-08-07 | -$502.00K 10-Q · filed 2015-05-15 | -$28.82K derived: sum of 2 quarters · filed 2017-08-07 | -$569.06K derived: sum of 3 quarters · filed 2017-08-07 | -$1.28M derived: sum of 4 quarters · filed 2017-08-07 | |||
| 2014-12-31 | $324.03K derived: 10-K 12 month − 10-Q 9 month · filed 2017-06-19 | -$216.21K derived: sum of 2 quarters · filed 2017-06-19 | -$924.04K derived: sum of 3 quarters · filed 2017-06-19 | -$1.91M 10-K · filed 2017-06-19 | -$2.69M 10-K · filed 2015-04-14 | |||
| 2014-09-30 | -$540.24K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-13 | -$1.25M derived: sum of 2 quarters · filed 2014-11-13 | -$2.24M 10-Q · filed 2014-11-13 | -$2.70M derived: sum of 4 quarters · filed 2014-11-13 | ||||
| 2014-06-30 | -$707.83K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-19 | -$1.70M 10-Q · filed 2014-08-19 | -$2.16M derived: sum of 3 quarters · filed 2014-08-19 | -$2.87M derived: sum of 4 quarters · filed 2014-08-19 | ||||
| 2014-03-31 | -$988.00K 10-Q · filed 2014-05-14 | -$1.45M derived: sum of 2 quarters · filed 2014-05-14 | -$2.16M derived: sum of 3 quarters · filed 2014-05-14 | |||||
| 2013-12-31 | -$462.77K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-27 | -$1.17M derived: sum of 2 quarters · filed 2014-03-27 | -$2.54M 10-K · filed 2014-03-27 | |||||
| 2013-09-30 | -$709.32K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2013-11-08 | -$2.08M 10-Q · filed 2013-11-08 | ||||||
| 2013-06-30 | -$1.37M 10-Q/A · filed 2013-09-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |